Outcome of relapse in children and adolescents with B‐cell non‐Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study

Abstract

Survival of children/adolescents with mature B-cell lymphoma/leukemia remains poor after relapse with no apparent improvement with rituximab. Response rates to salvage chemo-immunotherapies are insufficient and new drugs are urgently needed to improve disease control.